Literature DB >> 33966079

Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 European countries.

Kornelia Kotseva1,2, Guy De Backer2, Dirk De Bacquer3, Lars Rydén4, Arno Hoes5, Diederick Grobbee5, Aldo Maggioni6,7, Pedro Marques-Vidal8, Catriona Jennings2, Ana Abreu9, Carlos Aguiar10, Jolita Badariene11,12, Jan Bruthans13, Renata Cifkova13, Kairat Davletov14, Mirza Dilic15, Maryna Dolzhenko16, Dan Gaita17, Nina Gotcheva18, Hosam Hasan-Ali19, Piotr Jankowski20, Christos Lionis21, Silvia Mancas17, Davor Milićić22, Erkin Mirrakhimov23,24, Rafael Oganov25, Nana Pogosova26, Željko Reiner27, Duško Vulić28, David Wood2.   

Abstract

BACKGROUND: European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) V in primary care was carried out by the European Society of Cardiology EURObservational Research Programme in 2016-2018. The main objective was to determine whether the 2016 Joint European Societies' guidelines on cardiovascular disease prevention in people at high cardiovascular risk have been implemented in clinical practice.
METHODS: The method used was a cross-stional survey in 78 centres from 16 European countries. Patients without a history of atherosclerotic cardiovascular disease either started on blood pressure and/or lipid and/or glucose lowering treatments were identified and interviewed ≥ 6 months after the start of medication.
RESULTS: A total of 3562 medical records were reviewed and 2759 patients (57.6% women; mean age 59.0 ± 11.6 years) interviewed (interview rate 70.0%). The risk factor control was poor with 18.1% of patients being smokers, 43.5% obese (body mass index ≥30 kg/m2) and 63.8% centrally obese (waist circumference ≥88 cm for women, ≥102 cm for men). Of patients on blood pressure lowering medication 47.0% reached the target of <140/90 mm Hg (<140/85 mm Hg in people with diabetes). Among treated dyslipidaemic patients only 46.9% attained low density lipoprotein-cholesterol target of <2.6 mmol/l. Among people treated for type 2 diabetes mellitus, 65.2% achieved the HbA1c target of <7.0%.
CONCLUSION: The primary care arm of the EUROASPIRE V survey revealed that large proportions of people at high cardiovascular disease risk have unhealthy lifestyles and inadequate control of blood pressure, lipids and diabetes. Thus, the potential to reduce the risk of future cardiovascular disease throughout Europe by improved preventive cardiology programmes is substantial. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  EUROASPIRE; Primary prevention; cardiovascular risk factors; guideline implementation

Mesh:

Year:  2020        PMID: 33966079     DOI: 10.1177/2047487320908698

Source DB:  PubMed          Journal:  Eur J Prev Cardiol        ISSN: 2047-4873            Impact factor:   7.804


  16 in total

1.  Benefits and Risks Associated with Low-Dose Aspirin Use for the Primary Prevention of Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Control Trials and Trial Sequential Analysis.

Authors:  Mingming Wang; Haijie Yu; Zuojing Li; Daxin Gong; Xiaoxi Liu
Journal:  Am J Cardiovasc Drugs       Date:  2022-05-16       Impact factor: 3.571

2.  Secondary prevention in diabetic and nondiabetic coronary heart disease patients: Insights from the German subset of the hospital arm of the EUROASPIRE IV and V surveys.

Authors:  S Störk; P U Heuschmann; K Ungethüm; S Wiedmann; M Wagner; R Leyh; G Ertl; S Frantz; T Geisler; W Karmann; R Prondzinsky; C Herdeg; M Noutsias; T Ludwig; J Käs; B Klocke; J Krapp; D Wood; K Kotseva
Journal:  Clin Res Cardiol       Date:  2022-09-27       Impact factor: 6.138

3.  Antihypertensive strategies and hypertension control in Sub-Saharan Africa.

Authors:  Pauline Cavagna; Méo Stéphane Ikama; Kouadio Euloge Kramoh; Jean Laurent Takombe; Ibrahima Bara Diop; Ibrahim Ali Toure; Dadhi M Balde; Anastase Dzudie; Beatriz Ferreira; Martin D Houenassi; Murielle Hounkponou; Adama Kane; Suzy G Kimbally-Kaki; Samuel Kingue; Charles Kouam Kouam; Emmanuel Limbole; Liliane Mfeukeu Kuate; Jean Bruno Mipinda; Roland N'guetta; Carol Nhavoto; Jean Marie Damorou; Abdallahi Sidy Ali; Bamba Gaye; Gabriel S Tajeu; Diane Macquart de Terline; Marie Cécile Perier; Michel Azizi; Xavier Jouven; Marie Antignac
Journal:  Eur J Prev Cardiol       Date:  2021-09-20       Impact factor: 7.804

Review 4.  Management of Dyslipidaemia in Real-world Clinical Practice: Rationale and Design of the VIPFARMA ISCP Project.

Authors:  Ricardo Lopez Santi; Felipe Martinez; Adrian Baranchuk; Alvaro Sosa Liprandi; Daniel Piskorz; Alberto Lorenzatti; Maria Pilar Lopez Santi; Juan Carlos Kaski
Journal:  Eur Cardiol       Date:  2021-04-27

Review 5.  [COVID-19 and its relationship with hypertension and cardiovascular disease].

Authors:  M Salazar; J Barochiner; W Espeche; I Ennis
Journal:  Hipertens Riesgo Vasc       Date:  2020-06-18

6.  Polypill eligibility and equivalent intake in a Swiss population-based study.

Authors:  Julien Castioni; Nazanin Abolhassani; Peter Vollenweider; Gérard Waeber; Pedro Marques-Vidal
Journal:  Sci Rep       Date:  2021-03-25       Impact factor: 4.379

7.  A Similar Lifetime CV Risk and a Similar Cardiometabolic Profile in the Moderate and High Cardiovascular Risk Populations: A Population-Based Study.

Authors:  Małgorzata Chlabicz; Jacek Jamiołkowski; Wojciech Łaguna; Paweł Sowa; Marlena Paniczko; Magda Łapińska; Małgorzata Szpakowicz; Natalia Drobek; Andrzej Raczkowski; Karol A Kamiński
Journal:  J Clin Med       Date:  2021-04-09       Impact factor: 4.241

Review 8.  Lifestyle management to prevent atherosclerotic cardiovascular disease: evidence and challenges.

Authors:  T J van Trier; N Mohammadnia; M Snaterse; R J G Peters; H T Jørstad; W A Bax
Journal:  Neth Heart J       Date:  2021-11-11       Impact factor: 2.380

9.  Cost-effectiveness of rivaroxaban plus aspirin (dual pathway inhibition) for prevention of ischaemic events in patients with cardiovascular disease: on top optimisation of secondary prevention medication in the context of COVID-19 pandemia.

Authors:  Bernhard Rauch
Journal:  Eur J Prev Cardiol       Date:  2020-04-17       Impact factor: 7.804

10.  The Effect of a WeChat-Based Tertiary A-Level Hospital Intervention on Medication Adherence and Risk Factor Control in Patients With Stable Coronary Artery Disease: Multicenter Prospective Study.

Authors:  Kefei Dou; Weihua Song; Boqun Shi; Xi Liu; Qiuting Dong; Yuxiu Yang; Zhongxing Cai; Haoyu Wang; Dong Yin; Hongjian Wang
Journal:  JMIR Mhealth Uhealth       Date:  2021-10-27       Impact factor: 4.773

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.